Emcure Pharmaceuticals Ltd Financials
Company Logo

Emcure Pharmaceuticals Ltd Financial Statement

Emcure Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue1002.80
Operating Expense855.11
Net Profit40.45
Net Profit Margin4.03
Earning Per Share2.23
EBIDTA146.01
Effective Tax Rate8.74

Emcure Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual3,107.09
Operating Expenses Annual2,668.59
Operating Profit Annual557.70
Interest Annual166.83
Depreciation156.51
Net Profit Annual160.06
Tax Annual52.28

Emcure Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Cash Flow at the Beginning-393.35
Cash Flow from Operations505.37
Cash Flow from Investing-270.56
Cash Flow from Financing-54.52
Cash Flow at the End-213.05

Emcure Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
PBDIT Margin (%)17.95
PBIT Margin (%)12.20
PBT Margin (%)12.13
Net PROFIT Margin (%)5.15
Return On Networth / Equity (%)9.01
Return On Networth /Employed (%)10.71
Return On Assets (%)4.53
Total Debt / Equity (X)0.91
Asset Turnover Ratio (%)0.88

Emcure Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual1,268.20
Total Current Assets Annual2,159.41
Non Current Assets Annual2,456.44
Total Shareholders Funds Annual1,841.87
Total Assets Annual4,615.85

Emcure Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

7.95

Reported

7.95

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Jun 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Emcure Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
No, Emcure Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 0.91.
In FY 2023 , Emcure Pharmaceuticals Ltd recorded a total revenue of approximately 3,107.09 Cr marking a significant milestone in the company's financial performance.
Emcure Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and -0.0% annually, respectively..
Emcure Pharmaceuticals Ltd's current PE ratio is undefined.
Emcure Pharmaceuticals Ltd's ROCE averaged 17.1% from the FY ending March 2021 to 2023, with a median of 18.5%. It peaked at 22.4% in March 2022, reflecting strong capital efficiency over the period..
Emcure Pharmaceuticals Ltd's latest EBIT is Rs. 379.17 Cr, surpassing the average EBIT of Rs. 607.17 Cr over the 5 years..